These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10784624)

  • 1. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
    Tidefelt U; Liliemark J; Gruber A; Liliemark E; Sundman-Engberg B; Juliusson G; Stenke L; Elmhorn-Rosenborg A; Möllgård L; Lehman S; Xu D; Covelli A; Gustavsson B; Paul C
    J Clin Oncol; 2000 May; 18(9):1837-44. PubMed ID: 10784624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
    Sonneveld P; Burnett A; Vossebeld P; Ben-Am M; Rosenkranz G; Pfister C; Verhoef G; Dekker A; Ossenkoppele G; Ferrant C; Yin L; Gratwohl A; Kovacsovics T; Vellenga E; Capdeville R; Löwenberg B
    Hematol J; 2000; 1(6):411-21. PubMed ID: 11920222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
    Dorr R; Karanes C; Spier C; Grogan T; Greer J; Moore J; Weinberger B; Schiller G; Pearce T; Litchman M; Dalton W; Roe D; List AF
    J Clin Oncol; 2001 Mar; 19(6):1589-99. PubMed ID: 11250987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
    Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
    Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
    Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
    Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.
    den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
    Leukemia; 1998 Jun; 12(6):912-20. PubMed ID: 9639420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
    Berman E; McBride M; Lin S; Menedez-Botet C; Tong W
    Leukemia; 1995 Oct; 9(10):1631-7. PubMed ID: 7564501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia.
    Kokenberg E; Sonneveld P; Sizoo W; Hagenbeek A; Löwenberg B
    J Clin Oncol; 1988 May; 6(5):802-12. PubMed ID: 3163363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.
    Varatharajan S; Panetta JC; Abraham A; Karathedath S; Mohanan E; Lakshmi KM; Arthur N; Srivastava VM; Nemani S; George B; Srivastava A; Mathews V; Balasubramanian P
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1051-1058. PubMed ID: 27738808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry.
    Kokenberg E; Sonneveld P; Delwel R; Sizoo W; Hagenbeek A; Löwenberg B
    Leukemia; 1988 Aug; 2(8):511-7. PubMed ID: 3166077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia.
    Galettis P; Boutagy J; Ma DD
    Br J Cancer; 1994 Aug; 70(2):324-9. PubMed ID: 7914424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
    Gruber A; Björkholm M; Brinch L; Evensen S; Gustavsson B; Hedenus M; Juliusson G; Löfvenberg E; Nesthus I; Simonsson B; Sjo M; Stenke L; Tangen JM; Tidefelt U; Udén AM; Paul C; Liliemark J
    Leuk Res; 2003 Apr; 27(4):323-8. PubMed ID: 12531223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
    Bates SE; Bakke S; Kang M; Robey RW; Zhai S; Thambi P; Chen CC; Patil S; Smith T; Steinberg SM; Merino M; Goldspiel B; Meadows B; Stein WD; Choyke P; Balis F; Figg WD; Fojo T
    Clin Cancer Res; 2004 Jul; 10(14):4724-33. PubMed ID: 15269145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias.
    Damiani D; Michieli M; Ermacora A; Candoni A; Raspadori D; Geromin A; Stocchi R; Grimaz S; Masolini P; Michelutti A; Scheper RJ; Baccarani M
    Haematologica; 1998 Apr; 83(4):290-7. PubMed ID: 9592977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
    Styczyński J; Wysocki M; Debski R; Kurylak A; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
    Acta Biochim Pol; 2002; 49(1):99-107. PubMed ID: 12136962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia.
    Merlin JL; Guerci AP; Marchal S; Bour C; Colosetti P; Kataki A; Guerci O
    Br J Haematol; 1998 Nov; 103(2):480-7. PubMed ID: 9827923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
    O'Brien MM; Lacayo NJ; Lum BL; Kshirsagar S; Buck S; Ravindranath Y; Bernstein M; Weinstein H; Chang MN; Arceci RJ; Sikic BI; Dahl GV
    Pediatr Blood Cancer; 2010 May; 54(5):694-702. PubMed ID: 20209646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
    Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
    J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia.
    Bogason A; Masquelier M; Lafolie P; Skogastierna C; Paul C; Gruber A; Vitols S
    Drug Metab Lett; 2010 Dec; 4(4):228-32. PubMed ID: 20670211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between pharmacokinetics and efficacy and toxicity of daunorubicin in children with acute leukemia].
    Sun YN; Chai YH; Xu YJ; Lü H
    Zhonghua Er Ke Za Zhi; 2009 Apr; 47(4):296-300. PubMed ID: 19555570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.